Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The transformative trends occurring in the Huntington's disease treatment market reflect efforts that are being made continually to address this complex neurodegenerative disorder and provide innovative therapeutic solutions. One noteworthy trend is the development of disease-modifying therapies targeted at the underlying genetic cause of Huntingdon’s disease. Improvements in genetics and molecular biology have resulted in investigation of gene silencing techniques such as antisense oligonucleotides (ASOs) and RNA interference (RNAi) which aim at reducing the production of mutant huntingtin protein causing the illness.
Also, symptom management and supportive care are the main areas of focus aimed at improving patients’ lives with Huntington’s disease. Although there is no cure presently available, drugs targeting specific symptoms including chorea and psychiatric disturbances are under development. Further, various approaches involving physical therapy, and occupational therapy coupled with psychological support among others have shown effective strategies to manage diverse Huntington’s disease symptoms.
Additionally, biomarker research in early detection as well as monitoring progression constitutes another developing feature present in this market for treating Huntingdon's Disease. Identifying reliable biomarkers can enable early intervention/monitoring therapy response effectiveness. The trend is indicative ongoing moves to improve diagnostic accuracy track progression streamline creation targeted therapies.
Moreover, there is a growing trend towards patient registries and collaborative research initiatives within the field of Huntington's disease treatment. This is with the aim of global and national patient registries, which are collecting comprehensive data on patients suffering from Huntington’s disease facilitating joint research efforts.
Another important trend is related to digital health technologies used for managing Huntington’s Disease. Mobile applications, wearable devices, and telemedicine platforms are being used to remotely monitor symptoms, offer educational materials, and improve patient-provider communication regarding this condition. This development corresponds with greater usage of digital health technologies to improve patient involvement, accessibility, and healthcare management.
Furthermore, there is an emphasis on patient and caregiver support programs within the market for treating Huntington’s disease. Recognizing that individuals suffering from Huntington's disease (HD) are faced with emotional, social and financial difficulties; such support programs assist them navigate through their respective healthcare systems, accessing relevant resources along with coping with how HD affects their daily life. In doing so, this movement focuses more attention on holistic compassionate care besides medical interventions.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Market Opportunities | New product launches and R&D Amongst major key Players |
Huntington’s Disease Treatment Market Highlights:
Global Huntington’s Disease Treatment Market Overview
Huntington’s Disease Treatment Market is expected to reach USD 2.9 Billion rise steadily at a CAGR of 17.7% during forecast period of 2023-2032. This rise is due to high RandD speculations for new product improvement, research collaboration, and the high HD burden in European countries. Huntington’s disease is an infrequent inherited neurodegenerative disease that affects various generations.
The impact of this disease is high when the age is between 30 and 50, hampering their ability to work, care for families, and eventually complete daily tasks. The generality differs by more than ten-fold between geographical areas, which can be associated with differences in case ascertainments and diagnostic criteria. As a result, the generality of enlarged replications in the general population may be larger than expected. The Asian population has continuously had a lower generality, while Europe, North America, and Australia have a higher generality.
Huntington’s Disease Treatment Market Segment Insights
Huntington’s Disease Treatment Market is segmented into drug type, treatment and end-users.
Huntington’s Disease Treatment Drug Type Insights
On basis of drug type the Huntington’s Disease Treatment Market is segmented into tetrabenazine, deutetrabenazine, selective serotonin reuptake inhibitor (SSRI), chlorpromazine,haloperidol, risperidone, olanzapine, clozapine another drug type.Based on treatment the market is further segmented into two types such as symptomatic therapy and disease-modifying therapy.On basis of end-users the market is further segmented into hospital, clinics, retail pharmacies, online pharmacies and others.
Huntington’s Disease Treatment Regional Insights
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Huntington’s Disease Treatment Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of traumatic brain injury market. The European Huntington’s Disease Treatment industry has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Global Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market of huntington’s disease treatment in the Middle East & Africa has been segmented into the Middle East and Africa.
Global Huntington’s Disease Treatment Market Share (%), by Region, 2017 
Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon
Geographically, the America holds the highest market share for huntington’s disease treatment market and the reason being many market players are engaged in development of new drug product innovation. According to the survey carried out by one of the University of Sheffield, the estimated prevalence of huntington’s disease in North America, North Western Europe and Australia ranges from 5.96 to 13.7 cases per 100 000 population.
Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of targeted population, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region.
The prevalence of huntington’s disease is significantly lower in Asian populations compared to Western Europe, North America and Australia.
The market in the Middle East & Africa is likely to account for the smallest share of the global huntington’s disease treatment.
Huntington’s Disease Treatment Market Key players
Some of the key players in the Market are
- lnylam Pharmaceuticals Inc.
- AmpliPhi Biosciences Cor
- Ceregene Inc.
- Lundbeck
- Prana Biotechnology Limited
- Teva Pharmaceutical Industries Ltd.
- Cortex Pharmaceuticals Inc
- Vertex Pharmaceuticals Incorporated
- Auspex Pharmaceuticals
- SOM Biotech
- GlaxoSmithKline
- Siena Biotech, Raptor Pharmaceutical
- Pfizer
- Palobiofarma
- Omeros Ipsen
- Valeant Pharmaceuticals International Inc.
Huntington’s Disease Treatment Market Segmentation
Huntington’s Disease Treatment Drug Type Outlook
- Tetrabenazine
- Deutetrabenazine
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Chlorpromazine
- Haloperidol
- Risperidone
- Olanzapine
- Clozapine
- Other
Huntington’s Disease Treatment Treatment Outlook
- Symptomatic Therapy
- Disease-Modifying Therapy
Huntington’s Disease Treatment End-Users Outlook
- Hospital
- Clinics
- Online Pharmacies
- Retail Pharmacies
- Others
Huntington’s Disease Treatment Region Outlook
- Americas
- North America
- US
- Canada
- South America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Republic of Korea
- Rest of Asia Pacific
- The Middle East & Africa
- Middle East
- Africa
Recent Development
The major players, such as Neurocrine Bioscience, Inc. and Azevan Pharmaceuticals, Inc. are concentrating on research and improvement of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an innovative drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a medicine that does its work by blocking vasopressin 1 a receptor in the brain. However, presently approved medicines give symptomatic and palliative care and do not target the fundamental cause of the disease. In addition, medications can reduce the seriousness of symptoms, they are often connected with unfavorable effects such as somnolence, gait issues, dysphagia, and apathy, which can have adverse impacts on a patient’s quality of life. Given the inefficiency of a cure for the disease, it is censorious to evaluate how health-related quality of life is affected in these patients.
Intended Audience:
-
- Manufacturers and Suppliers
- Hospitals and Clinics
- Laboratories and Associations
- Research and Development (R&D) Companies
- Government research institutes
- Academic institutes and universities
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
